The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia

First-line nilotinib in chronic myeloid leukemia is more effective than imatinib to achieve early and deep molecular responses, despite poor tolerability or failure observed in one-third of patients. The toxicity and efficacy of tyrosine kinase inhibitors might depend on the activity of transmembran...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Galimberti, Sara, Bucelli, Cristina, Arrigoni, Elena, Baratè, Claudia, Grassi, Susanna, Ricci, Federica, Guerrini, Francesca, Ciabatti, Elena, Fava, Carmen, D’Avolio, Antonio, Fontanelli, Giulia, Cambrin, Giovanna Rege, Isidori, Alessandro, Loscocco, Federica, Caocci, Giovanni, Greco, Marianna, Bocchia, Monica, Aprile, Lara, Gozzini, Antonella, Scappini, Barbara, Cattaneo, Daniele, Scortechini, Anna Rita, La Nasa, Giorgio, Bosi, Alberto, Leoni, Pietro, Danesi, Romano, Saglio, Giuseppe, Visani, Giuseppe, Cortelezzi, Agostino, Petrini, Mario, Iurlo, Alessandra, Di Paolo, Antonello
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2017
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5675690/
https://ncbi.nlm.nih.gov/pubmed/29152138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21406
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים